Literature DB >> 17479442

Prescription of insulin glargine in primary care practices in Germany.

W Rathmann1, B Haastert, P Riebel, D Schroeder-Bernhardi, K Kostev, E Huppertz, G Giani.   

Abstract

BACKGROUND: New classes of antidiabetic medications have been introduced, but details of their use are not well known. The aim was to assess prescription patterns and dosing for insulin glargine (market launch: 6/2000) in primary care patients.
METHODS: Computerized data on prescriptions (Disease Analyzer, 6/1999 to 8/2003) from 277 general and internal medicine practices throughout Germany were analysed (67,402 diabetic patients; 340 incident glargine (age: 67+/-12 years) and 378 incident NPH users (66+/-11 years).
RESULTS: Diabetes prevalence in the practices increased over the three-year period (5.1% to 6.2%). The highest increase was observed for insulin treated patients (+29%), followed by diet (+21%) and oral antidiabetics (+19%). Premixed insulin (short-acting insulin and NPH) remained constant as largest insulin group. A continuous increase of short-acting insulin analogues was found (+70%). Long-acting insulin analogues (glargine) increased threefold. Glargine was more often prescribed in combination with oral antidiabetics than NPH (76% vs 49%; p<0.05). Only about a quarter received short-acting insulin (NPH: 61%; p<0.05). The cumulative annual dose was higher among NPH users (geometric mean; NPH: 7971 IU; glargine: 5719 IU) (p<0.01), which persisted after adjusting for age, sex, and morbidity (p<0.01).
CONCLUSIONS: Diabetes prevalence continuously increased in German primary care practices from 1999 to 2003. The largest increase was found for insulin treatment, in particular, for short and long-acting insulin analogues. Insulin glargine was more often prescribed in combination with oral agents, whereas NPH insulin was more frequently prescribed with short-acting insulin, indicating different prescription patterns in primary care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17479442     DOI: 10.1055/s-2007-972562

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  4 in total

1.  Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study.

Authors:  Marloes Dankers; Karin Hek; Marjorie Nelissen-Vrancken; Sebastiaan T Houweling; Aukje Mantel-Teeuwisse; Liset van Dijk
Journal:  Br J Gen Pract       Date:  2022-05-26       Impact factor: 6.302

2.  Non-adherence to guideline recommendations for insulins: a qualitative study amongst primary care practitioners.

Authors:  M Dankers; M J E van den Berk-Bulsink; M van Dalfsen-Slingerland; H J M G Nelissen-Vrancken; A K Mantel-Teeuwisse; L van Dijk
Journal:  BMC Prim Care       Date:  2022-06-13

3.  Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China.

Authors:  Guangxu Liu; Jingtao Dou; Yuesong Pan; Yuxiang Yan; Huiping Zhu; Juming Lu; Herbert Gaisano; Linong Ji; Yan He
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-29       Impact factor: 5.555

4.  Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes.

Authors:  Virginia Bellido; Lorena Suarez; Maria Galiana Rodriguez; Cecilia Sanchez; Marta Dieguez; Maria Riestra; Florentino Casal; Elias Delgado; Edelmiro Menendez; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2015-10-12       Impact factor: 19.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.